₂₈ 2016 10 22 23 TFT 1 ₁ ₁ 1, 1, 1, 1, 2, 3, 3, 3 1, 2, 3 B-Flow,., B-Flow. 3. 1 B Flow. 2,. 3. 3 1, 2, 3.,,. Logiq S8 GE. ₁ ₂ 1, 1, 1, 1, 2, 3, 3, 3 1, 2, 3 B.,.,,.,,. Depth 6 cm..,,,,.,. ₁ ₃,,,. 3,.3 3, 3..,.. 2 ₂ ₁ 1, 1, 1, 1, 1, 1, 1, 1, 3, 2 1, 2, 3,.,. 48. 5.,,,.3 A,,..,,,. 3. ₂ ₂ 1 1, 2, 2, 2, 2, 1, 1, 2 1, 2. 1
₂ ₃ 1 1, 1, 1, 1, 1, 1, 2, 2, 1, 1 1, 2 60. 8 CRT-D,7 2.1, Staphylococcus epidermidis,, CRT-D. TEE 3 33 21 mm, 10 6 mm,20 10 mm. 9 CRT-D,,10 mm. 2 TEE, 6 TEE.TEE. ₂ ₄,,,,,, 48..,., 58, - 15. 6,., 18. 6,. ST.,,,.,. 3 ₃ ₁ 1,,,,,,,,, 40,.1,.,...,.,,,. A 1 stage,.,,.,,.. ₃ ₂,,,,,, 45. CT 20 mm.mri T 2 WI, CT,.,,.EUS,,,.,,.IgG4,PSL. FDG-PET SUVmax: 3. 08,., S-100. 30,.,. ₃ ₃ 1, 1, 1 2, 1 3, 4 1, 2, 3, 4.,. 16 16 mm..b, SPN,. CT,, 15 mm. CT,.,. B,. ₃ ₄ 1, 1, 1, 1, 1, 2 1, 2 66,.,.TSH 0. 005 IU/ml,FT4 0. 53 ng/ ml,ft3 1. 47 pg/ml,tgab 210 IU/ml,TPOAb 600 IU/ml,.40 123 I,TSH 100. 000 IU/ml,FT4 0. 09 ng/ml,ft3 0. 29 pg/ ml,,. TRAb 40. 0 IU/l,TSAb 3, 930.7 TSH 100. 000 IU/ml,FT4 0. 02 ng/ml,ft3 2
0. 26 pg/ml, T4.. 1 ₁ ₁ 1 1, 1, 1, 1, 1, 1, 1, 2, 1 1, 2 60 2 12 mm.1 17 mm, CT. 39 mm 2.,,. HBs HCV. CT,., steatohepatitis Stage 1 Graide 1 NASH... ₁ ₂ 17 1 1, 1, 2, 1, 1, 1, 1, 1, 1, 1 1, 2 C SVR., SVR 17 C 1. 80.1993 C,1999.Genotype 2a,HCV-RNA 6 IFN.SVR.2016 3 S 5 25 mm. US CT MRI,Child A., clear cell type. F 1 /A 1.C SVR 15. ₁ ₃ 1 1, 1, 1, 1, 1, 1, 1, 1, 2, 3 1, 2, 3 78,.C.., S 4 20 mm,3. S 4 28 mm.,,.,..,ki-67,l-fabp,gs,β-catenin,saa,crp, I-HCA. HCA. I-HCA,,SAA SAA-HN. ₁ ₄ 1, 1, 2, 2, 2, 3, 3, 3, 4 1, 2, 3, 4 24.,.,,.,,..Sonazoid CEUS 3,,. focal nodular hyperplasia FNH,CT MRI,Gd-EOB-DTPA FNH., fibrolamellar hepatocellular carcinoma FLC. FLC CEUS. ₁ ₅,,,,,,,,,, TACE CEUS.,TACE CT CEUS,. TACE 146. CT, CEUS., 1. RECICL. 27. 17 CT TE 4,CEUS TE 3.1 CT 17 TE 3. CEUS,. 3
2 ₂ ₁ 1 1 1, 2, 1, 2, 1 2, 3 1, 2, 3 HCC. 50,,. 30,. S 3 20 mm,..., Washout. EOB-MRI.,,HMB 45., 1. ₂ ₂ 1 2 1, 2, 1, 2, 1 2, 3 1, 2, 3 HCC noduleinnodule. 60, 2,US. US, S 8 27 mm,,,, nodule in nodule,. CT,EOB- MRI,,., HMB45,. nodule in nodule, 1. ₂ ₃,,,,, haml,,,., HCC, HCC.. haml. 1991 2015 haml 8 3, 5, 44 30 67. 5 3 36, 36 mm 16 52 mm, 5, 2, 1. 5, 2, 1, 4, 4.B 1. 5, 2, 1. 8. ₂ ₄ 1 1, 1, 1, 1, 1 2, 2, 2 3, 3, 3, 4 1, 2, 3, 4 41,..CT 8 cm.. 8 cm 6 cm.,,,..,,..,...,.,.,,. ₂ ₅ 1, 1, 1, 1, 1, 1, 1, 1, 2, 2 1, 2 71,.C 7,., CT.CT,. 34 mm.,, wash out,,.,,igg,cd20,cd79a,mum-1,cd138, bcl-1,.,.. ₂ ₆ 1, 2, 2, 1 1, 2 Focal nodular hyperplasia FNH B.FNH,,,B,. FNH 66. 23 4
85 50, 38 28, 43. 8 65 mm 18 mm,b, 90. 75. FNH,,. 3 ₃ ₁ 1, 1, 1, 1, 1, 1, 3, 2, 2, 1 1, 2, 3 GE B US,,.,., 2. 71,ALC.2011. 11 CT L/Sp 0. 85,US,2 L/ Sp 1. 25,US, 4,L/Sp 0. 65,US. 33,CH-C.2013. 8,US,, 2014. 11,US. 60-80.. ₃ ₂ 1, 2, 1 2. ₃ ₃,,,,,,,,,,,.,, SOL,SWE. 2016 6 7 SWE 60, SOL 15. l,sol.,,,,..,.,.,. SOL. ₃ ₄ 1 1, 1, 2, 2, 1, 1, 1, 1, 1, 1 1, 2 Child-Pugh C 3 30. 7,3 MELD score MELD 20 29 76,30 39 83, 40 100. C-P C. 40.2011.2012 2013, VTQ 4. 23, C-Pscore 13,MELDscore 30., 1 3. 67,2 3. 62 VTQ,3 2. 87... ₃ ₅,,,,,,,,,,C DAAs, SVR., DAAs share wave elastography SWE. DAAs, SWE 30.SWE,. GE LOGIQ E9, Aplio500.., SWE. SWE.,DAAs, DAAs,. ₃ ₆,,,,,,,,,,., 1 / 3 Regev. 2012,.SWE B,. 5
. 2016 6 7 SWE 30. 3,3, Transient elastography TE. LOGIQ E9 GE.,,,..TE,3,. SWE. ₃ ₇ 3 1, 1, 1, 1, 1, 2, 2, 2, 3, 1 1, 2, 3 Fontan,.,., 21 24, 23 25, 17 19 3. Fontan 10, 3 30. 10.,. CT,.,. ₃ ₈ 1, 1, 1, 1, 1, 1, 1, 2, 2, 2 1, 2, ROI. ROI,. 30.LOGIQ S8 GE. Fibroscan echosens.roi.,metavir score,,. METAVIR score,. ROI,. 4 ₄ ₁ 1 1, 1, 1, 1, 1, 1, 1, 1, 1, 2 1, 2 80,.1990 25, US,., US. 2010 US sludge,2015 11 US,. 2 3 US,,. US..,.,.,. 25,. ₄ ₂ 1 1, 1, 1, 1, 1, 1, 2, 2, 3 1,, 2 3 50,.2013 12 US, 4 mm,2014 12 US.2015 12 US, 6 mm,,. US,., 60 mm, mp T1b.,,... ₄ ₃ 1 1, 1, 1, 1, 1, 1, 1, 1, 1, 2 1, 2 40,.,.,. Rokitansky-Ashoff sinus 6
,. 25 mm.,.,,.., 30 mm...,.. ₄ ₄ 1,,,,,,,,, 40,.2.1, PD-1.,,., 27 mm.,,,,.,mri,t 1 WI,T 2 WI,, PET-CT FDG 7. 12.,. 28 mm,,.. ₄ ₅ 1 1, 1, 1, 1, 1, 1, 1, 1, 1, 2 1, 2 80, 20,12. ALP, GTP,CT. US RHD,LHD,B 2,B 3,B 4,Bc,Bs 24 mm.lhd,b 2, B3,B4,.RHD Bs,.. CT 22 mm,. LHD B 4,.,.,. ₄ ₆ 1, 2, 3, 5, 4, 6, 7, 3 1, 2, 3, 4, 5, 6, 7. ₄ ₇ 1 1, 1, 1, 1, 1, 2, 2, 3 1, 2, 3 66,..,. CT MRCP.,.ERCP,,..,.. B 6,B 7,.,..,.,. 5 ₅ ₁ 1 1, 1, 1, 1, 1, 1, 1, 1, 1, 2 1, 2 70,. ESD, ESD. CA 19-9 804,CT..24 mm,,,,....,.,.,.,... 7
₅ ₂ 1 1 3, 1 3, 2, 3 1 JA, 2 JA, 3 IPMN 1. 50. US. US. 5 mm,, 3,, D 2. CT MRI CT MRI,IPMN.. US,IPMN.,. IPMN 1. ₅ ₃ 1 1, 1, 1, 1, 1, 1, 1, 1, 1, 2 1, 2,WHO Intraductal papillary-mucinous neoplasm IPMN ITPN.ITPN, IPMN 1.,ITPN 1. 70. CT. 63 mm.,,., 11 mm.vater.,ipmn ITPN. ITPN.. ₅ ₄ 1 1, 1, 1, 2, 2, 3, 1 1, 2, 3 pnet US,., pnet 1. 26.., SPN. US 115 103 mm.,.,. CT.,.,pNET. pnet,,. 1. ₅ ₅ 1, 1, 2 1, 2. ₅ ₆ 1 1, 1, 1, 1, 1, 1, 2, 2, 3, 3 1, 2, 3 77,. US,,. US 19 18 mm.,,.,,. CT,. MRI T 1,T 2,,dynamic.,. 21. 6, 1. 3.,,,.. 6 ₆ ₁ 1,,,,,,,,, 70. SMT,.,, 60 mm Delle SMT.,., strong echo,delle. 8
,.GIST malignant potential SMT,., hyperchromatic. Chromogranin,Ki67 index 2 NET G1.6 cm,. ₆ ₂ 1 1, 1, 1, 1, 2, 2, 2, 3, 3, 4 1, 2, 3, 4 73,..,,.., 4. 3... SS., M, SM. Bmode,..,. ₆ ₃ 1 1, 1, 1, 1, 1, 1, 2, 2, 2 1, 2 NET., NET. 40,.3, 9 cm. 10 cm,,, 12.,., NET.,. ₆ ₄ 1, 1, 2, 3 1, 2, 3 60.,.,,,.. 2, 1,., 3..,. ₆ ₅ 1, 1, 1, 1, 2, 2, 3, 3 1, 2, 3 2015 9 1 10 31 113, CT,US.,,. 29 US,CT 12,CT 10,US 1, 6, 23 CT,US 9,CT 9,US 5,US 5, 15 US,CT 2,CT 13,US 0, 12 CT,US 6, CT 5,US 1.,CT US,US. CT,US,. ₆ ₆ 1, 1, 1, 2, 2 1, 2,,.,,., 30,. 30 30, 3 2.,,,, UP.,,,. 9
₆ ₇ 1, 1, 1, 2, 2 1, 2,,,.,,., 3 3, 000. 147 cm 188 cm, 20 82.,,. 1 ₁ ₁ 1, 2 1, 2 78..,,.,.,Ⅰ,Ⅱ, 1989,.,.,,. ₁ ₂ 1 1, 2, 1, 1, 1, 1, 1, 2, 2 1, 2 1. 31.TTE,,.TTE., TEE,.. CT PLSVC, CS. CS,.CS PLSVC, CS,PLSVC. ₁ ₃ 2 1, 2, 1, 1, 1, 1, 1, 2, 3, 2 1, 2, 3 1 70.MR,TR,Af,,. 6,.CT MRI,,.,. 2 70.MsR,TR,Af,,.5, CT,.,.MRI,.,,. 2,. ₁ ₄ 1 1, 1, 1, 1, 1, 1, 2 1, 2 47.,..,,.,,.. CT.,,. PPI proton pump inhibitor,,.1,., CT..CT.2,. ₁ ₅,,,,,, 72.,,.,, 35., 19 16 mmhg,.,,..,, dip and plateau pattern, CP,. 10
... ₁ ₆ 1 1, 4, 1, 1, 3, 3, 3, 2, 2 1, 2, 3, 4 Superb Micro-vascular Imaging SMI, CT,. 84,, EVAR,, Type Ⅱ,. CT,,, SMI.,. SMI.EVAR, SMI. 2 ₂ ₁ 1, 1, 1, 1, 1, 1, 1, 1, 2, 2 1, 2 72,.., 7 mm...,,..... ₂ ₂ 1, 2 1, 2 45, A.,,,,.,,,.,..,,,. ₂ ₃ 1 1, 2, 1, 1, 1, 1, 1, 2, 2, 2 1, 2 67,.,,. 10 mm, 35 mm.,.,..,.,,,.. ₂ ₄ 1 1, 1, 1, 1, 1, 1, 2, 1 3 1, 2, 3 50.2 1 km,2. ST,.,. 80,, 2 m s 15.,, 6 90,.,. ₂ ₅ 1, 1, 1, 1, 1, 1, 1, 2, 2 1, 2 24, 19,.20 11
.. 1,,.,. 60 46 mm,, 22 mmhg.,.,, 4., 2. 3.,,,.,. 3 ₃ ₁ 1, 1, 1, 1, 1, 1, 1, 2, 2, 2 1, 2 SAM, AR SAM. SAM. 2014 1 2016 7 AR 40,SAM 6 6, 62 17 AR,ARjet, SAM. AR 3, 2, 1.ARjet 63 5 mm, 64 9.SAM,. AR SAM, AR,. ₃ ₂ 1, 2, 2, 2, 1 1, 2..,,,.,PISA,vena contracta, reversal flow..,.,.,,.,.,,. ₃ ₃ 2 1, 2, 2, 2, 2, 2, 2, 1, 1, 1 1, 2 CHADS 2. 132. IMT 1. 1 mm, 15 mm 45 mm PS. PS 92 ; 70. 5, PS ; 12. 3, CHADS 2 ; 2. 3.CHADS 2 PS r 0. 44,p 0. 001.CHADS 2 0 PS; 3. 4 1. 8 CHADS 2 3 PS; 15. 0 1. 0 PS. CHADS 2,. ₃ ₄ 1, 2, 2, 1, 1, 1, 1, 2, 1 3, 1 4 1, 2, 3, 4 70.,,.. EF 33,,.,. PSV 277 cm/s,edv 65. 5 cm/s,rar 3. 31, AT 150 ms,.. PSV 181 cm/s,rar 1. 98, AT 60 ms.,,. 12
₁ 1, 1, 1, 1, 2, 3, 1 1, 2 &, 3. ₂ 1, 1, 1, 1, 1, 2, 2, 2 1, 2,., 23.,.MRI,.,.,,,. ₃ 1, 1, 2, 2, 2 1, 2 Modality fusion,ge Volume Navigation V-Navi GPS 3D-US, fusion., 3D, fusion.. 20.,,,. ₄ 1 2, 2, 3, 1 2, 1, 2, 1 2, 1 2, 1, 1 1, 2, 3 Neuroendocrine carcinoma. 49,.. Neuroendocrine carcinoma ER,PgR, HER-2,Ki-67 : 40. Bp Ax.T 1 N 0 M 0 StageI. 50 Gy,2 LH-RH 5 Tamoxifen. 10, C 12 mm,. MRI.... Neuroendocrine carcinoma ER, PgR,HER-2,Ki-67 : 50,T 1 N 0 M 0 StageI. ₅ 2 1 1 3, 1 3, 2, 3 1 JA, 2, 3,E., US,2 CE 1. 70.,C,, 3 cm.us CE 36 mm.,,,., US. ₆ 1, 1, 1, 1, 2, 2, 2 1, 2 16.1 CT,,,,, CT 13
.CT,,,, MRI,US. MRI,,., target,,., IMT.IMT, IMT. ₇ 1, 1, 2, 3, 1 1 JMA, 2 JMA, 3 63.2015 12,. 12 1 cm,,.mmg Ⅰ.US 19 10 16 mm,,,,,d W 0. 53, US. CT...2016 5 US 16 7 14 mm,d W 0. 44...US. ₁ 1 1 2, 2, 3, 1, 1, 2, 1 2, 1 2, 1, 1 1, 2, 3 FAP. 41,.15 FAP.23,.,.35 CT. Class V..,T 3,N 1 b 8 / 16,M 0 stage I., no 6,38.40, Lenvatinib, 9,PR.FAP,. ₂ 1 1, 2, 2, 2, 2, 2, 1, 1, 1, 1 1, 2 72,.. 70, MALT.,,.,5.,,diffuse large B-cell lymphoma. R-CHOP,,.,... ₃,,,,, 48,.,.US 29 mm halo.,.,.40 US,., 15 12 mm 22 19 mm 2 mm 26 25 mm 27 26 mm 7 mm. 2 23 23 mm,28 23 mm,6 mm,.6,.,,. ₄ 1 1, 2, 1, 1, 1, 1, 1, 1, 3, 2 1, 2, 3 70 3.,,.,.,,.MRI,. T 1 WI,T 2 WI,. 14
,metastatic adenocarcinoma.ct spicula,.,. adenocarcinoma,. 1. ₅,,,,,, 26.17,.24. 26., 3 cm,. 28 23 11 mm.,,.,.,,,,.,.. ₆ 1, 2, 3, 2 1, 2, 3,.,,., 31, 30, 38 3, 5 MHz,.,,.,.,. ₁,,, 1. 2015 7 2016 6 842. 245 : 29. 1, 597 : 70. 9 NT NT 3. 5 mm 32 : 3. 8, 20 NT 13 : 2. 4, 50 NT 2 : 8. 4. 48 NT 20, 1, 27, 10 6. NT 8 4, 2. NT,,. ₂,,,,,. ₃ 1, 2, 1, 1, 1, 3 1, 2, 3. ₄ 1,,,,,,,,,, 1-5. 28 0 0. 24, 25. 19 19 mm,,., ureteropelvic junction stenosis: UPJ stenosis. 33,. 39 0. 3, 458 g,,apgar score 1 8,5 9., UPJ, 2,UPJ.,.. ₅ 1, 2, 1, 1, 1, 1, 1, 1, 3, 3 1, 2, 3.,27 3 2 cm, AFI: 13. 32,34,. 36,,37.2, 637 g, Apgar score: 8 / 9 1 / 5,., 15
, 7. 63.,,. ₁ 1 1, 2, 1, 1, 3, 1 1, 2, 3 Wunderlich,,.,. 14 2,.US.,,. MRI Wunderlich,. US,,,,.,. Wunderlich.US Wunderlich. ₂,,,,,,,,,, 8. 30,7,6. 8 6,,.,,.,,,..,, hcg,.,,,.,. ₃ 1,,,,, AVM,,.., 1.30 2 0,..Hb 5. 0 mg/dl.,.3d-ct angiography..,... ₄,,,, UAP,,94. 1 100.,,., UAP,. 36,3 1. 83,3 14 mm.doppler mode to-and-fro sign,uap.doppler.,,, UAP.UAP,. ₁ 6 1 1 1, 2, 1, 1, 1, 1, 1, 2, 3 1, 2, 3 AML,6 RCC 1. 71.2007 US,. 2009 8 mm,ct AML. 2011 12 mm,2013 17 mm,2014 22 18 mm.,ct,.2015 27 20 mm, US CT.MRI, RCC,. pt1a.rcc US. RCC AML. AML RCC,. 16
₂ 1, 2, 1, 3, 3 1, 2, 3,.. 20. 20,,,,,,,. 1 A, B. A B 20 19, 80, 100.. ₃ 1 1, 1, 1, 1, 1, 1, 1, 1, 2, 2 1, 2 64,. US,CT.. US 55 39 mm.,,,.. CT,..,..,,.US,,.. ₄ 1 1, 2, 2, 1, 2, 1 1, 2 17,.,,.. 41 41 53 mm.,.,..,.,. 1.. ₁ 1, 1, 2, 3, 2 1, 2, 3,,,.,. 250 MHz, 7 μm,.,,,.,,.,. ₂ 1, 1, 2, 3, 4, 2 1, 2, 3, 4,,., 5, 5,, 15 MHz,25 MHz,.,.,, 1 10-30 μm, 1.,., 2,. 17
₃ 1, 1 2 3, 3, 3 1, 2, 3.,USE MR MRE.., ACUSON S3000,Siemens VTQ VTIQ,3 T MRI MAGNETOM Verio,Siemens 62. 5 Hz MRE Vs. 2 cm Vs,VTQ VTIQ,MRE 1. 8 0. 1,2. 6 0. 1,2. 5 0. 6., Vs. 18